(Total Views: 427)
Posted On: 06/10/2025 1:45:17 AM
Post# of 154626
March 2025 Update
The Company continues to prioritize oncology in 2025, as we believe this indication holds the highest potential and shortest timeline for return on investment in the form of a partnership or drug approval.
___
"To accelerate progress in oncology where feasible, we’re establishing an oncology advisory board to ensure we are exploring the fastest and most responsible pathway(s) forward."
If they're working on releasing data on the remaining 30 - 60....it would kill the thoughts of our data is too small / limited
No trial in history has ever included 21 patients with brain metastasis
The Company continues to prioritize oncology in 2025, as we believe this indication holds the highest potential and shortest timeline for return on investment in the form of a partnership or drug approval.
___
"To accelerate progress in oncology where feasible, we’re establishing an oncology advisory board to ensure we are exploring the fastest and most responsible pathway(s) forward."
If they're working on releasing data on the remaining 30 - 60....it would kill the thoughts of our data is too small / limited
No trial in history has ever included 21 patients with brain metastasis
(2)
(0)
